New PET scan agent may spot hidden GVHD in joints

NCT ID NCT07325253

Recruiting now Knowledge-focused Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing a new imaging agent called [18F]4FN in PET/CT scans for people with chronic graft-versus-host disease (GVHD) affecting their joints. The goal is to see if the agent is safe and can help doctors see joint problems more clearly. Sixteen adults with chronic GVHD will receive the agent by IV and then have a PET/CT scan. The study focuses on safety and how well the imaging works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]4FN (an imaging agent given by IV)
What this could lead to: If successful, this could lead to a better way to see and measure chronic GVHD in joints using PET/CT scans, helping doctors diagnose and monitor the condition more accurately.
What could go wrong: This is a very small, early pilot study with only 16 participants, so results may not apply to everyone. The main goal is safety and feasibility, not yet proving the imaging works for diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic graft versus host disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HOST DISEASE MANIFESTATION PET/CT IMAGING PILOT STUDY

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.